Katina Dorton - 20 May 2026 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Reporting relationship: Director
Issuer ticker: TCRX
Reported as of: 20 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2026, 16:05:13 UTC
Prior SEC filing: 25 Feb 2026
Next SEC filing: 04 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Zoran Zdraveski, Attorney-in-Fact

Key filing fact

Katina Dorton filed Form 4 for TScan Therapeutics, Inc. (TCRX) on 22 May 2026.

Key facts

This page summarizes Katina Dorton's Form 4 filing for TScan Therapeutics, Inc. (TCRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 May 2026, 16:05.

Change

Previous filing in this sequence was filed on 25 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001617541 Primary reporting owner

Dorton Katina

Relationship: Director
Address: C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM
Signature: /s/ Zoran Zdraveski, Attorney-in-Fact
Signature date: 22 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TCRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +67,000
Change %
Price: $0.000000^*
Shares after: 67,000
Date: 20 May 2026
Ownership: Direct
Underlying class: Voting Common Stock
Underlying amount: 67,000
Exercise price: $0.9946
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.